A report appearing in an American Cancer Society journal, CA: A Cancer Journal for Clinicians, says clinicians should be aware of and should consider the expenses of new interventions such as PET for staging cancer. "Unless clinicians, other cancer health care providers, and cancer researchers are active participants in discussions regarding the relative costs and benefits of new interventions, others will make ... cost-effectiveness conclusions," the authors wrote.

Full Story:

Related Summaries